TheEdgeResearch
Home / Stocks / ABTI

Alterola Biotech, Inc. (ABTI)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$291,900
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
1.52
52-Wk Range
0.000199999995-0.2
CEO
David John Hitchcock
Country
GB
Currency
USD

Alterola Biotech, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Birkenhead, MR, GB. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $291,900. On trailing twelve-month figures it carries a trailing P/E of -0.11, a net margin of 0.0%. Its beta of 1.52 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.11
Price / Sales
0.00
Price / Book
0.02
EV / EBITDA
-1.00
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.14
Current ratio
0.11
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
2010-05-05
Headquarters
Birkenhead, MR, GB
About Alterola Biotech, Inc.

Alterola Biotech, Inc. is a pharmaceutical company dedicated to the research and development of cannabinoid and cannabinoid-like molecules. The firm primarily focuses on pioneering regulated pharmaceutical products for human and animal health, as well as regulated food items. Key activities also include the production of active pharmaceutical ingredients (APIs) and food-grade components. Furthermore, the company emphasizes drug formulation and advanced delivery systems to improve bioavailability, solubility, and overall stability. It operates out of Birkenhead, United Kingdom.

Comparable companies

Alterola Biotech, Inc. is most often compared with the following Healthcare names:

BHCCFBHHKFCMVLFCPHRFDMTRFEDTXFIDGXFMAYNFNIKAONVVF
More research on ABTI
ABTI technical analysis ABTI TheEdge Score Compare against peers
Open full interactive analysis & DCF →